# R1 Clinical-Safety Review — malignant_spinal_cord_compression

VERDICT: APPROVE

Reviewed against DeVita, Hellman & Rosenberg 12th ed. (Spinal Cord Compression chapter) as cited, cross-checked with the adversarial-verify verdict (.verdict.md = CLEAN, no unresolved ISSUES).

## 1. SAFETY — pass
No unsafe, misleading, or over-absolute statement found. The narrative is safety-forward in the right places:
- Lymphoma steroid-before-biopsy pitfall is called out (prevents the classic diagnostic-obscuring error).
- "New back pain in a known/suspected cancer patient = possible cord compression until proven otherwise, urgent imaging" — correct low-threshold red-flag framing.
- >72h complete deficit = low recovery likelihood, unstable spine = surgical emergency, <3-month life expectancy caveat for surgery — all consistent with standard of care.
- Steroid claims are hedged (very-high "trauma-protocol" regimens explicitly not recommended; more is not better) — no harm risk.

## 2. GROUNDING — pass
Treatment claims align with DeVita/NCCN standard of care: histology-first triage, corticosteroids on suspicion, MNOP (ISOC) definitive-treatment framework, radiosensitivity tiers, Patchell-type surgery+RT benefit with the elderly-subgroup caveat, separation surgery + SBRT for radioresistant histology, radium-223 short path-length limitation for epidural disease. Non-DeVita items (gastroprotection, VTE prophylaxis, log-roll precautions) are explicitly labeled as general oncology standard rather than attributed to DeVita. No fabricated or outdated regimen. No claim mis-attributed to DeVita.

## 3. DOSE-FREE — pass
No mg, mg/m2, AUC, Gy, or numbered fractionation schedule anywhere. All numeric tokens are non-dose: clinical timing (72h), prognostic word-thresholds (~2mo / ~3mo), Bilsky grade integers (0–3), isotope name (radium-223), citation edition (12th). Source doses (10 vs 100 mg dexamethasone, Gy values, mm margins, local-control %) are all correctly rendered qualitatively.

## 4. SCOPE — pass
Appropriately hedged as decision-support, not a directive ("often", "generally", "most likely", "individualised rather than uniform"). Surgery-vs-RT decision explicitly framed as individualized/multidisciplinary. Structured-content items (Bilsky full scale, SINS, dose/fractionation) correctly deferred to calculators/protocol templates.

## 5. ADVERSARIAL FLAGS — no unresolved blocking issues
The .verdict.md is CLEAN; both prior R1 hard-gate issues (Bilsky disclaimer/body contradiction; grade 0/1 SBRT over-generalization) are fixed in the current sidecar. The only carryover is a non-blocking cosmetic note, not an ISSUE requiring REVISE.

## Advisory (non-blocking, fix opportunistically)
- "Role of systemic therapy" 2nd sentence duplicates the grounded 1st sentence and carries an inverted label ("general oncology standard, not from DeVita") for content that IS in DeVita. This under-attributes (safe direction, opposite of the dangerous case); recommend deleting the redundant sentence to remove the mislabel. Not a safety or grounding failure.

goldens changed: no (intended: n)
